文献速递类风湿关节炎

类风湿关节炎患者使用糖皮质激素与改善病情抗风湿药的感染风险

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2021-01-01

该综述评估了类风湿关节炎(RA)治疗中糖皮质激素、传统合成改善病情抗风湿药(DMARDs)、生物制剂及JAK抑制剂相关的严重感染及其他关键感染风险。传统合成DMARDs安全性良好,甲氨蝶呤相对安全;TNF抑制剂增加严重感染风险,其他生物制剂和JAK抑制剂风险总体相似,但JAK抑制剂带状疱疹风险更高;糖皮质激素对严重感染风险呈剂量依赖性,高剂量时风险显著高于其他免疫调节治疗,低剂量时风险与生物制剂相似。

要点

  • 传统合成DMARDs安全性良好,甲氨蝶呤有近期数据支持其相对安全性。
  • TNF抑制剂增加严重感染风险,其他生物制剂和JAK抑制剂风险总体相似。
  • 糖皮质激素感染风险呈剂量依赖性,低剂量亦与生物制剂风险相似。

核心结论

  • 糖皮质激素对严重感染风险呈剂量依赖性,高剂量时风险显著高于其他免疫调节治疗,低剂量时风险与生物制剂相似。

研究设计与样本

  • 综述,评估RA主要治疗药物类别(糖皮质激素、传统合成DMARDs、生物制剂、JAK抑制剂)的严重感染及其他关键感染风险。

主要发现

  • 传统合成DMARDs安全性良好,近期数据支持甲氨蝶呤的相对安全性。
  • TNF抑制剂与严重感染风险增加相关。
  • 其他生物制剂和JAK抑制剂风险略有差异但总体与TNF抑制剂相似,JAK抑制剂带状疱疹风险更高。
  • 糖皮质激素高剂量时感染风险显著高于其他免疫调节治疗,低剂量时风险与生物制剂相似。

临床怎么用

  • 治疗决策时应了解不同药物的感染风险,并据此适当监测患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory therapy for rheumatoid arthritis (RA) carries risk for infectious complications. Understanding the risks of different therapeutic options is essential for making treatment decisions and appropriately monitoring patients. This review examines data on the risks for serious infections and other key infections of interest for the major classes of agents in use for RA: glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biologics and Janus kinase (JAK) inhibitors. Conventional synthetic DMARDs have an excellent safety profile with recent data available supporting the relative safety of methotrexate. Tumour necrosis factor (TNF) inhibitors are associated with an increase in the risk of serious infections. Risk with other biological agents and with JAK inhibitors varies somewhat but overall appears similar to that of TNF inhibitors, with JAK inhibitors also associated with a greater risk of herpes zoster. Glucocorticoids have a dose-dependent effect on serious infection risk-at higher doses risk of infection with glucocorticoids is substantially greater than with other immunomodulatory therapies, and even low-dose therapy carries a risk of infection that appears to be similar to that of biological therapies.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Riley TR, George MD. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. 2021. PMID: 33597206. doi:10.1136/rmdopen-2020-001235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。